Scholarlink

Purpose <p>To characterize the clinicopathological features and metabolic profiles of silent growth hormone pituitary adenomas (SGH-PAs).</p> Methods <p>The single-center retrospective study identified SGH-PAs from 1387 surgically treated non-functioning PAs at Peking Union Medical College Hospital (2019–2023). Controls included 407 consecutive cases with non-functioning gonadotropin pituitary adenomas (NFG-PAs) and 90 age and gender-matched acromegaly patients. Baseline and postoperative hormonal assessments, pituitary imaging features, pathological classification, metabolic comorbidity, and follow-up outcome were collected and analyzed.</p> Results <p>45 cases of SGH-PA (3.2%) were identified from 1387 non-functioning PAs. The pathological subtypes included 18 (40%) acidophil stem cell adenomas, 11(24%) immature PIT1-lineage tumors, 5 sparsely granulated GH tumors, 5 mammosomatotroph tumors, 4 mature plurihormonal PIT1 lineage tumors, and 2 plurihormonal pituitary tumors. Compared to controls, SGH-PAs showed modestly elevated proliferation (median Ki-67 3% vs. 2% in both acromegaly [<i>p</i> = 0.002] and NFG-PAs [<i>p</i> = 0.011]) without outstanding increases in tumor invasiveness (Knosp 3–4: 20–30% across groups) at baseline or 2-year recurrence. Baseline metabolic comorbidities paralleled NFG-PA profiles for hypertension (22%) and diabetes (8.9%), with reduced dyslipidemia prevalence (17.8% vs. 33.4%, <i>p</i> = 0.049). No case of SGH-PAs transforming into acromegaly was confirmed during 77 person-years of follow-up.</p> Conclusions <p>SGH-PAs represent approximately 3% of nonfunctioning PAs undergoing surgery. Multiple anterior pituitary hormones are commonly co-expressed. These tumors may be more proliferative, but the baseline aggressiveness in radiology and short-term recurrence rates are similar.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Silent growth hormone pituitary adenomas: a single-center study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月11日

查看全文
  • Tongxin Xiao,
  • Xinxin Mao,
  • Xueqing Zheng,
  • Ran Li,
  • Linjie Wang,
  • Yong Yao,
  • Kan Deng,
  • Fengying Gong,
  • Hui Pan,
  • Lin Lu,
  • Huijuan Zhu,
  • Lian Duan

摘要

Purpose

To characterize the clinicopathological features and metabolic profiles of silent growth hormone pituitary adenomas (SGH-PAs).

Methods

The single-center retrospective study identified SGH-PAs from 1387 surgically treated non-functioning PAs at Peking Union Medical College Hospital (2019–2023). Controls included 407 consecutive cases with non-functioning gonadotropin pituitary adenomas (NFG-PAs) and 90 age and gender-matched acromegaly patients. Baseline and postoperative hormonal assessments, pituitary imaging features, pathological classification, metabolic comorbidity, and follow-up outcome were collected and analyzed.

Results

45 cases of SGH-PA (3.2%) were identified from 1387 non-functioning PAs. The pathological subtypes included 18 (40%) acidophil stem cell adenomas, 11(24%) immature PIT1-lineage tumors, 5 sparsely granulated GH tumors, 5 mammosomatotroph tumors, 4 mature plurihormonal PIT1 lineage tumors, and 2 plurihormonal pituitary tumors. Compared to controls, SGH-PAs showed modestly elevated proliferation (median Ki-67 3% vs. 2% in both acromegaly [p = 0.002] and NFG-PAs [p = 0.011]) without outstanding increases in tumor invasiveness (Knosp 3–4: 20–30% across groups) at baseline or 2-year recurrence. Baseline metabolic comorbidities paralleled NFG-PA profiles for hypertension (22%) and diabetes (8.9%), with reduced dyslipidemia prevalence (17.8% vs. 33.4%, p = 0.049). No case of SGH-PAs transforming into acromegaly was confirmed during 77 person-years of follow-up.

Conclusions

SGH-PAs represent approximately 3% of nonfunctioning PAs undergoing surgery. Multiple anterior pituitary hormones are commonly co-expressed. These tumors may be more proliferative, but the baseline aggressiveness in radiology and short-term recurrence rates are similar.